Probable Rare Case of Cholecystitis After Exposure to Supratherapeutic Doses of Hydralazine.

Objective

To report a rare case of cholecystitis in a patient who received supratherapeutic doses of hydralazine for 1 month. Case Summary: A 79-year-old woman was admitted with severe right upper quadrant abdominal pain. Three weeks prior, she suffered a similar episode and was told she had a buildup of sludge in her gall bladder. For the past month, she had inadvertently received 400 mg of hydralazine per day instead of 150 mg; she was also prescribed fenofibrate 145 mg daily. Her workup was remarkable only for a slightly elevated white blood cell count and gall bladder sludge and distention without common duct obstruction. She was diagnosed with cholecystitis and underwent a laporoscopic cholecystectomy within 72 hours of admission. She was subsequently discharged a day later with the corrected hydralazine dose, and she has not been readmitted to the hospital. Discussion: Hydralazine is a direct acting vasodilator that may also potentiate the effects of nitric oxide. Nitric oxide has been linked to decreased gall bladder motility in in vivo and in vitro studies. The Naranjo algorithm indicates that this is a probable adverse event of fenofibrate and of hydralazine; the Drug Interaction Probability Scale indicates that this case of cholecystitis was a possible result of the interaction between hydralazine and fenofibrate. Based on the time course of the patient's medication use and symptoms, hydralazine is more likely to be the cause of her cholecystitis than her other medications.

Conclusion

Clinicians should be aware that high doses of hydralazine may inhibit gall bladder motility and contribute to the buildup of bile sludge.